Scientists launch biobank to unlock secrets of early kidney disease
NCT ID NCT02936791
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study is collecting blood and urine samples from 250 people with early-stage polycystic kidney disease (PKD), their unaffected family members, and healthy volunteers. The goal is to create a biobank that researchers can use to find biological markers of disease progression. This knowledge could help develop better treatments for PKD in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify early signs of disease progression, leading to better treatments for polycystic kidney disease.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly benefit participants, and findings may take years to translate into new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2016
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The Study Population will include individuals clinically diagnosed with PKD and meet the inclusion criteria, their family members with not been diagnosed or have been determined not to have cysts within their kidneys and normal volunteers that will serve as a control group for the study.
- Ages
-
4 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD): * Family history of PKD * All races and ethnic groups * Glomerular filtration rate (GFR) \>80 ml/min per 1.73 m2 * Inclusion for Healthy Volunteers: * Male or female with no family history of kidney disease * All races and ethnic groups * Normal GFR Exclusion Criteria: * Non-insulin or insulin-dependent diabetes mellitus * Systemic illness (i.e.systemic lupus erythematosus, vasculitis) * Unable to provide written informed consent * Unavailable for magnetic resonance imaging (MRI) and blood/urine collection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Polycystic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's Mercy Hospital
RECRUITINGKansas City, Missouri, 64108, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.